News & Updates
Filter by Specialty:
Osimertinib after CRT safe, effective in unresectable stage III EGFR-mutated NSCLC
Treatment with osimertinib following definitive chemoradiotherapy (CRT) demonstrates a manageable safety profile in patients with unresectable stage III EGFR-mutated nonsmall cell lung cancer (NSCLC), reports a study presented at WCLC 2024.
Osimertinib after CRT safe, effective in unresectable stage III EGFR-mutated NSCLC
07 Oct 2024
Aspirin may improve survival in PIK3CA-mutated colon cancer
Adjuvant treatment with aspirin appears to provide some protection in patients with resected, PIK3CA-mutant stage II and III colon cancer, demonstrating a clinically significant improvement (43 percent) in disease-free survival (DFS), suggests a study presented at ESMO Congress 2024.
Aspirin may improve survival in PIK3CA-mutated colon cancer
06 Oct 2024
Pulmonary arterial hypertension outcomes better with early therapy augmentation with selexipag
In the treatment of patients with pulmonary arterial hypertension, adding selexipag as a third medication sooner rather than later is crucial to help prevent hospitalization and disease progression, as suggested in an emulated target trial.
